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Summary Background: In asthma exacerbations, higher doses of inhaled beta-
agonists are used to overcome acute bronchoconstriction. Traditionally, wet
nebulisation has been used, but metered-dose inhaler with a spacer device is an
alternative delivery method. Objective: To compare the clinical outcomes in adults
and children with acute asthma, presenting in emergency departments or in the
community, who have been randomised to beta-agonists given by two different
delivery. Methods: a metered-dose inhaler with spacer or a nebuliser. Results: A
Cochrane review has found no important differences between the two delivery
methods in adults. Children may suffer fewer side effects with spacer delivery.
Conclusions: Individual response to treatment cannot be predicted, but many studies
overcame this problem by using frequent repeated doses of beta-agonists (one
respule via nebuliser or four separate actuations of a metered-dose inhaler through a
spacer) every 10–15min, titrated against the clinical response of the patients. This
approach is advocated in clinical practice.
r 2003 Elsevier Science Ltd. All rights reserved.
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Background
Acute exacerbations of asthma remain common in
spite of the increasing use of prophylactic medica-
tion and pose a regular challenge to medical
services, both in hospital and in primary care.
Treatment with increased doses of inhaled beta-
agonists is often required for exacerbations, in
addition to other agents such as corticosteroids and
oxygen. In order to relieve bronchospasm effec-
tively the beta-agonist needs to be delivered to the
peripheral airways. This is made more difficult in
acute asthma since the narrowed airways and
faster respiratory rate result in increased drug
deposition in the throat and large airways.
In order to combat this problem of delivery, two
different methods can be employed: wet nebulisa-
tion and metered-dose inhaler (MDI) with a spacer
(holding chamber). Nebulisation can be accom-
plished with room air or supplemental oxygen, and
requires a supply of compressed gas or a power
source. High doses of beta-agonist are put into the
nebulisation chamber (typical up to 25 times the
dose from a MDI), but much of this dose is lost into
the atmosphere and never reaches the patient’s
airways.
More recently, beta-agonists delivered via MDIs
through a spacer have been used in acute asthma.
The inhaler is actuated into the chamber that is
then emptied by the patient using either tidal
breathing or single breaths. It should however be
noted that compliance with the usual instructions
to take a deep breath and then hold it for several
seconds is not possible for patients with acute
exacerbations of asthma.
There is much debate about the relative merits
of each delivery method. Whilst nebulisers have
traditionally been used in acute exacerbations of
asthma, a meta-analysis of trials in adults with
asthma or chronic obstructive pulmonary disease
(COPD) suggested that MDIs with a spacer are as
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effective.1 In addition, cost and infection control
considerations may be important additional deter-
minants of which system is employed. For example,
in the community the cost of using a nebuliser
exceeds that of a spacer and MDI. In hospital
emergency departments, the cost calculations are
more complex since disposable nebuliser masks are
often driven by piped oxygen; costs may depend on
whether or not all patients are sent home with a
new holding chamber. Nebulisers represent a
potential source of cross-infection, and require
regular maintenance.
Whilst nebulisation in hospital is usually oxygen
driven, most portable nebulisers used by patients in
their homes and carried by general practitioners
are air driven. Portable oxygen cylinders can be
used to nebulise beta-agonists but a high-flow valve
is required for this purpose.
This overview seeks to address some of the
practical issues involved in comparing nebulisation
and spacers as delivery devices in acute asthma,
and uses the Cochrane systematic review (updated
in 2001) as source material.2
Objectives
The objective of the Cochrane review was to
compare the clinical outcomes following the use
of beta-agonists in people with acute asthma
presenting in the community or in hospital emer-
gency departments. Delivery with MDI and spacer
was compared to delivery with nebuliser.
Problems with comparing delivery
methods
There are several methodological difficulties in
comparing the devices used in delivery of beta-
agonists. The main problem is confounding by the
dose of beta-agonist administered. An unknown
proportion of the nominal delivered dose will reach
the lungs of the recipient, and this will vary
according to the technique used in inhalation, the
severity of the exacerbation and the type of
nebuliser or spacer employed. Secondly there are
issues relating to a possible placebo response from
treatments that patients have found effective in
the past (such as nebulised beta-agonists), as acute
asthma can be a very frightening experience and
accompanied by anxiety that increases the diffi-
culty in breathing. Thirdly there may be differences
between children and adults in their use of the
devices and response to beta-agonists, and there
may be differences between the community and
hospital settings.
Deciding which studies to use
Study design and participants
In order to reduce the problems of bias the
Cochrane review comparing delivery methods
sought out only randomised controlled trials. Trials
were not excluded on the basis of being unblinded,
but were required to use the same drug through
nebuliser or spacer. Children and adults with acute
asthma were included who were treated for acute
asthma in emergency departments or in the
community. Infants were not included, so trials on
small children with a mean age of under 2 years
were excluded. Also patients who were already
hospitalised have not been included in the review
at present, but will be incorporated at a future
date.
Studies on patients with COPD were excluded,
but a meta-analysis of trials in adults with asthma
or COPD has been published showing similar results
to the Cochrane review.1
Outcome measures
The primary outcome measure for the review was
hospital admission. This was chosen because it was
thought that avoiding admission was important to
people suffering acute asthma attacks (and to their
families). Secondary outcomes included duration in
the emergency department, change in lung func-
tion, pulse and respiratory rates, and change in
oxygen saturation.
Review methods
The methods used to carry out the review are
described in detail elsewhere.2 A comprehensive
search was carried out using the Cochrane Airways
group trials register, and no trials were excluded on
the basis of language or publication status. The
review has been updated twice since it was first
published in 1996. Two reviewers independently
assessed the full text of papers to check whether
the inclusion criteria were met, and to assess
the methodological quality of the trials using the
method proposed by Jadad et al.3 This method
scores for whether allocation of treatment was
adequately concealed during randomisation of
the patients, whether there is blinding of the
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participants and assessors, and whether withdra-
wals and dropouts are described. Sensitivity analy-
sis was carried out to check the results if only trials
of higher methodological quality were considered,
and where heterogeneity between the results of
different trials was found this was explored.
Description of included studies
The studies come from all over the world. All
studies excluded patients who were suffering from
life-threatening asthma. Only one was carried out
in the community;4 all others were conducted in
hospital emergency departments.4–25 The single
pre-hospital study comparing nebulisation to
spacer26 was excluded as there was no randomisa-
tion. Different beta-agonists, holding chambers and
nebulisers were represented in the studies. The
dosage ratio between delivery methods varied from
1:1 to 1:13 in favour of the holding chamber. The
dosing schedule also varied from a single treatment
to multiple treatments at 10–30min intervals.
In general, the sample size of individual studies
was small (range 18–152 patients). Whilst six of the
nine studies in adults were double blind7,9,18,19,21,22
only four of the 13 studies in children was double-
blind.10,11,15,17 Overall, the methodological quality
of the included studies was variable. Only two of
the included trials commented on the number of
potentially eligible patients excluded from the
study, but Chou reported that all the eligible
children presenting with acute asthma to the
emergency department agreed to participate in
their study.6 Many studies did not comment on
withdrawals and dropouts, and also did not report
whether intention to treat analysis was employed.
The hospital admission rate reported in one study
was amended using an intention to treat analysis.7
Using titrated treatment to overcome
confounding by dose delivered
The studies included in this review used dosage
ratios varying from 1:1 to 1:13 (lower dose in the
spacer). One of the included studies plotted a log
dose-response curve;7 the equivalent dose ratio
found in this study was 1:6 with the lower dose in
the holding chamber. It should be noted, however,
that the dose ratio found in this study cannot be
assumed to be identical for other nebulisers and
holding chambers. Moreover none of the studies
was carried out with the newer inhalers that use
CFC-free propellants, which in turn could alter the
effective dose ratio between devices.
In clinical practice, the dose of beta-agonist
reaching the airways varies depending on the type
of nebuliser or holding chamber used, the nominal
dose administered and the characteristics of the
individual patient’s airways at that time.27 Uncer-
tainty over the dose of beta-agonists required
through any delivery method was overcome
in several of the later studies by using short
treatment intervals: for example one respule
(via nebuliser) or 4–6 puffs (via holding chamber)
every 10–30min until the patient responded to
treatment.5–7,9,11,15,18–20,23
This titrated approach neatly overcomes the
difficulties of knowing how much beta-agonist is
needed for each patient. Each treatment builds on
the previous one and as the bronchoconstriction
eases the subsequent doses should be better able to
reach the airways.
In adults, no additional benefit was found using 6
puffs of Salbutamol (100mcg each) given at 10min
intervals through a Volumatic Spacer, when com-
pared with 4 puffs at 10min intervals.28 A compar-
ison in children between doses of 0.5 and 1.5mg/kg
given at 20min intervals via nebuliser showed
significantly greater improvement in lung function
at the higher dose.29
The first version of the Cochrane review pooled
results from studies that used a single administra-
tion of beta-agonist with studies using multiple
treatments. In a more recent version of the review
these have been separated out, due to concern
over dose confounding in the single treatment
studies. The latter no longer contribute to the main
outcomes of the review.8,10,12,17,21
Results of the review
Of 112 abstracts originally identified from the
Airways group database, 44 were selected for
possible inclusion in the review. The full text of
each paper was obtained and translated when
necessary (two from Spanish and one from Portu-
guese). Studies were excluded for the following
reasons: 11 studies on hospitalised patients (these
represent a small subset of patients presenting with
acute asthma which are not typical of the overall
group, they will be incorporated as a separate
comparison in a future update of the Cochrane
review), 11 studies on non-acute asthma (as the
response to bronchodilators may be different), and
10 for other reasons (such as the use of different
beta-agonists in each arm of the trial). A total of
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12 papers were initially included for this review and
nine further papers have now been added so that
there are now 880 children and 444 adults in the
included trials.
Spacer vs. nebuliser using multiple
treatments
The primary outcome of the review was hospital
admission rates, and the relative risk (RR) of
admission did not differ on the basis of delivery
method in adults (RR¼ 0.88; 95% CI 0.56 to 1.38) or
in children (RR¼ 0.65; 95% CI 0.4 to 1.06).
Combining the results for adults and children gives
an overall relative risk of 0.77 (95% CI 0.40 to 1.06).
The point estimates were stable when studies of
lower methodological quality were excluded
(although the confidence intervals were wider),
and no significant heterogeneity was demonstrated
(Fig. 1). Two studies in children did not report
admissions but did report data on children whose
response to treatment was categorised as poor;5,11
when these are included the relative risk in
children of admission or poor outcome is not
significantly different between chamber and nebu-
liser (RR¼ 0.85; 95% CI 0.57 to 1.26). In order to
check for publication bias a funnel plot was
constructed, in which the effect size of each trial
was plotted against its weight. The funnel plot did
not show obvious asymmetry, so no evidence for
publication bias was found. No trials individually
showed a significant difference in admission rates
between the two delivery methods.
No significant differences were demonstrated
between the two delivery methods for lung func-
tion, change in respiratory rate, development of
tremor and the number of patients given steroids.
Interestingly, in the four studies in adults that
included analysis of changes in lung function in the
most severely affected patients (e.g. FEV1o30%
predicted), the weighted mean difference (WMD) in
FEV1 between the two delivery methods was not
significantly different (WMD¼1.6% predicted;
95% CI 7.69 to 4.49% predicted).
Symptom scores are important to patients but
could not be combined in the review as no measure
of the variance of the mean scores were reported in
the primary papers.
Exploring heterogeneity between trial
results
For some outcomes there was significant statistical
heterogeneity between the results of different
trials. In other words the results between trials
differed more than would be expected by chance,
starting from the hypothesis that all the trials were
sampling the same treatment effect. Fig. 2 shows
the duration of time spent in the emergency
department for two studies in adults9,18 WMD
0.02 h (95% CI 0.4 to 0.44) and one in children6
where the mean difference is –0.62 h (95% CI –0.84
to 0.44) in favour of the spacer.
When these two subgroups are compared, there
is significant heterogeneity between them (Chi-
square 8.2, degrees of freedom 2, P¼ 0.02), and
this cannot be explained on the grounds of study
quality as all three studies are of high quality
(Jadad score of 3 or more). The heterogeneity
disappears when the studies are split as shown in
Fig. 2. This could represent a genuine difference
between adults and children, especially as other
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Colacone 1/40 0/40
Idris 1/15 1/20
Rodrigo 5/49 4/48
Rodriguez 14/36 17/33
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Leversha 10/30 18/30
Ploin 3/31 3/32
19/183 28/170Sub-total
n/N n/NStudy Relative Risk
of Admission
(95% CI)
Favours
Chamber
Favours
Nebuliser
ADULTS 
CHILDREN
Turner 4/27 5/26
Chou 4/71 5/81
Williams 2/42 2/18
44/359 55/346Total
Fig. 1 Meta-analysis of the effect on hospital admission
of beta-agonist delivered by MDI and spacer compared to
nebuliser. The studies have been grouped as adults and
children. The intervals show the 95% confidence intervals
using a fixed-effect model. N¼ no. of patients in that
area of the study; n¼ no. of patients admitted to
hospital. Relative risks shown are from Ref. [2].
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Mean(SD) Mean(SD)
Idris 15 1.5(0.8) 20 1.7(0.9)
Rodrigo 93 49 2.2(1.7) 48 1.9(1.5)
Chou 71 1.1(0.5) 81 1.72(0.9)
71 81Sub-total
Fig. 2 Meta-analysis of the effect of duration in emergency department of beta-agonist delivered by MDI and spaces
compared to nebulisers. The studies have been grouped as adults and children. The intervals show the 95% confidence
intervals using a fixed-effect model. N¼ no. of Patients. Weighted Mean Difference shown are from Ref. [2].
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N NStudy Rise in pulse rate[% baseline]
WMD (95% CI)
Favours
Chamber
Favours
Nebuliser
ADULTS 
CHILDREN
Colacone 40 -1.0(19) 40 4.0(19)
Mean(SD) Mean(SD)
Idris 15 1.0(16) 20 0.0(18)
Rodrigo 93 49 -1.3(14) 48 -0.4(14)
Rodrigo 98 11 -10(20) 11 -2.0(20)
Rodriguez 36 -0.0(12) 33 -1.3(11)
Turner 27 -4.0(16) 26 -3.0(20)
Vazquez 9 -10(10) 9 0.0(8.0)
Chou 71 5.0(12) 81 15(17)
Batra 30 -13(9) 30 -7.4(12)
Leversha 30 0.1(7) 30 7.3(7)
178 178Sub-total
Fig. 3 Meta-analysis of the effect of pulse rate on beta-agonist delivered by MDI and spacer compared to nebuliser. The
studies have been grouped as adults and children. The intervals show the 95% confidence intervals using a fixed-effect
model. N¼ no. of Patients. Mean and standared deviation are shown for each area of the study. Weighted Mean
Differences shown on from Ref. [2].
766 C. Cates
outcomes show similar effects with children having
less side effects from the use of spacers in terms of
pulse rate (Fig. 3). In adults, the rate shows a WMD
of 0.82 (95% CI 3.92 to –2.27) per cent of base-
line, whilst in children there is a WMD of 7.78
(95% CI –10.21 to –5.34) in favour of the spacer.
Heterogeneity between the subgroups is significant
(Chi-square 11.98, degrees of freedom 2, P¼ 0.002).
However, caution is needed in the interpretation of
the findings of differences between subgroups.30 The
initial subgrouping into children and adults was not
specified in the original protocol and was therefore
post hoc when the review was first prepared. It has
been tested since by the addition of further trials,
which have strengthened the findings of differences
in relation to the advantage of spacers in children in
terms of pulse rate. A further study in children
comparing a homemade non-valved spacer with an
oxygen-driven nebuliser in 196 children in Brazil has
also shown a shorter duration in the emergency room
for the spacer group.31 The mean duration in the
emergency room was 41.1min for the spacer and
66.9min for the nebuliser (mean difference
25.8min, 95% CI 18.6 to 33min).
Moreover, the difference between the ages of
participants is only one of several possible explana-
tions for the discrepancy between the results in
children and adults. In particular, the children’s
study did not use a double-dummy design and was
not blinded to the participants (although the
clinician assessing patients for discharge did not
know which treatment the child had received). All
patients in the adult studies were given beta-
agonist or dummy treatment via both nebuliser and
spacer, and this may have slowed treatment times
(as nebulised treatment takes considerably longer
to give than spacer treatment). We cannot be sure
whether the advantages for the spacer in the
children’s study in terms of duration in the
emergency department are related to the fact
that children were being treated or due to other
factors.
Practical implications
Theoretical issues around titration and
implications for trial design and practice
In acute asthma, the lung delivery in individual
patients will depend on the degree of bronchocon-
striction, and the individual nebuliser or spacer
used (as well as the patient technique). For this
reason it makes sense to emulate the clinical trials
in using beta-agonists frequently (e.g. at 10min
intervals). Used in this way MDIs with spacer can
produce equivalent results to nebulised delivery.
The optimum average dose and delivery interval for
inhaled beta-agonists in acute asthma are un-
known, but since no advantage has been shown
using doses above 4 separate puffs every 10min
though a spacer,28 this approach is advocated for
community use (since nebulisers are more expen-
sive and less convenient than spacers). Oxygen can
be administered between spacer usage if required,
and the proven benefit of oral steroids in prevent-
ing relapse should not be forgotten.32
Whilst it may be more convenient to use
nebulised delivery in the hospital setting, it should
be remembered that this raises expectations for
future nebulised treatment in the community or for
subsequent exacerbations. A recent pragmatic
before and after study has confirmed that it is
possible to substitute MDI and spacer for nebuliser
delivery of beta-agonists in day-to-day emergency
department treatment of adults with acute asth-
ma.33 When using an MDI and spacer, patients were
initially treated with 5 puffs of albuterol (salbuta-
mol) and then 3–5 puffs every 20min as needed.
Duration of stay fell from an average of 175min to
164min, and both peak flow and arterial oxygen
saturation improved significantly more with the MDI
and spacer. Relapse rates were also lower but this
may have been affected by the provision of educa-
tional material, a peak flow meter, a spacer and
inhaled corticosteroids for the patients’ home use.
Children and adults
It is often assumed that adults and children respond
in the same way to asthma therapy, however, this
should not be taken for granted. It is better to
present results in children and adults as separate
subgroups. The overall impression gained from this
review is that spacers have some advantages in
children in reducing side effects such as tachycar-
dia. The reduced duration of stay in the Chou study
has been replicated in a further study in children
using a homemade spacer.31 Both studies were
unblinded and did not use a double-dummy design,
so it remains unclear whether this is a true
difference between the way children and adults
respond to a spacer and nebuliser, or whether
issues of study design confound the results.
Spacers and nebulisers in chronic asthma
Two further reviews have addressed the question of
spacers and nebulisers to deliver beta-agonists34
and inhaled corticosteroids35 in chronic asthma.
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The problem of confounding by dose delivered and
the paucity of trial data available make it im-
possible to draw firm conclusions about the relative
efficacy of the delivery methods in these reviews.
Practice points
* In children and adults with non-life-threa-
tening acute asthma beta-agonists admi-
nistered by MDI and spacer can be as
effective as nebulisation in acute asthma.
* In any individual patient with acute asth-
ma, delivery of inhaled bronchodilators to
the peripheral airways will depend upon
the degree of bronchoconstriction. Since
an unknown proportion of the drug will
reach its target, it is sensible to administer
repeated doses of beta-agonist at short
intervals and monitor the patient’s re-
sponse.
* Optimal delivery doses and intervals are
unknown, but the trials typically used one
respule via nebuliser or four MDI actuations
(given through a spacer and individually
inhaled with tidal breathing) at intervals of
10–30min.
* All the reported studies excluded patients
with life-threatening asthma. The conclu-
sions from this review of the available data
may not apply in this situation.
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